227 related articles for article (PubMed ID: 21402296)
21. Comparing the effectiveness of intranasal fentanyl spray with oral transmucosal fentanyl citrate in breakthrough pain.
Shellard SE; Ram FS
Int J Palliat Nurs; 2015 Oct; 21(10):475-8. PubMed ID: 26505081
[TBL] [Abstract][Full Text] [Related]
22. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
23. Fentanyl nasal spray for the treatment of cancer pain.
Mystakidou K; Panagiotou I; Gouliamos A
Expert Opin Pharmacother; 2011 Jul; 12(10):1653-9. PubMed ID: 21609189
[TBL] [Abstract][Full Text] [Related]
24. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients.
Farrar JT; Cleary J; Rauck R; Busch M; Nordbrock E
J Natl Cancer Inst; 1998 Apr; 90(8):611-6. PubMed ID: 9554444
[TBL] [Abstract][Full Text] [Related]
25. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer.
Portenoy RK; Taylor D; Messina J; Tremmel L
Clin J Pain; 2006; 22(9):805-11. PubMed ID: 17057563
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain.
Kaessner N; Nave R; Roepcke S; Facius A; Lahu G
Int J Clin Pharmacol Ther; 2012 Sep; 50(9):665-77. PubMed ID: 22784611
[TBL] [Abstract][Full Text] [Related]
27. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893
[TBL] [Abstract][Full Text] [Related]
28. The pharmacoeconomics of breakthrough cancer pain.
Kuo KL; Saokaew S; Stenehjem DD
J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):167-75. PubMed ID: 23688496
[TBL] [Abstract][Full Text] [Related]
29. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.
Überall MA; Müller-Schwefe GH
Curr Med Res Opin; 2011 Jul; 27(7):1385-94. PubMed ID: 21561313
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L
Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131
[TBL] [Abstract][Full Text] [Related]
31. Fentanyl buccal tablet: faster rescue analgesia for breakthrough pain?
Lecybyl R; Hanna M
Future Oncol; 2007 Aug; 3(4):375-9. PubMed ID: 17661711
[TBL] [Abstract][Full Text] [Related]
32. Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain.
Darbà J; Kaskens L; Sánchez-de la Rosa R
Clinicoecon Outcomes Res; 2013; 6():1-9. PubMed ID: 24368889
[TBL] [Abstract][Full Text] [Related]
33. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
Mercadante S; Prestia G; Adile C; Casuccio A
J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
[TBL] [Abstract][Full Text] [Related]
34. [Oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain].
Borgbjerg FM; Rosenberg J
Ugeskr Laeger; 2000 Sep; 162(39):5237-40. PubMed ID: 11043058
[TBL] [Abstract][Full Text] [Related]
35. The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study.
Mercadante S; Ferrera P; Arcuri E
Support Care Cancer; 2011 Mar; 19(3):435-8. PubMed ID: 20882391
[TBL] [Abstract][Full Text] [Related]
36. Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.
Mercadante S
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):9-13. PubMed ID: 25359295
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
Rauck RL; Tark M; Reyes E; Hayes TG; Bartkowiak AJ; Hassman D; Nalamachu S; Derrick R; Howell J
Curr Med Res Opin; 2009 Dec; 25(12):2877-85. PubMed ID: 19814586
[TBL] [Abstract][Full Text] [Related]
38. An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
Plock N; Facius A; Hartmann L; Baumann S; Nave R
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):495-508. PubMed ID: 23611571
[TBL] [Abstract][Full Text] [Related]
39. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study.
Hanks GW; Nugent M; Higgs CM; Busch MA;
Palliat Med; 2004 Dec; 18(8):698-704. PubMed ID: 15623166
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]